Cinctive Capital Management LP Buys New Holdings in Eli Lilly and Company $LLY

Key Points

• Cinctive Capital Management LP acquired 1,880 shares of Eli Lilly and Company stock, valued at approximately $1,553,000, during the first quarter of the year.
• Insider purchases included Director Gabrielle Sulzberger and CEO David A. Ricks, indicating confidence in the company's performance with recent transactions valued at $75,018 and $1,052,264 respectively.
• Eli Lilly's stock price recently opened at $742.22, with a twelve-month revenue increase of 37.6% year-over-year, reporting $15.56 billion for the latest quarter.

Cinctive Capital Management LP acquired a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,880 shares of the company's stock, valued at approximately $1,553,000.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Brighton Jones LLC lifted its holdings in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after buying an additional 40 shares during the period. Orion Capital Management LLC lifted its holdings in Eli Lilly and Company by 2.5% in the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock worth $1,243,000 after buying an additional 40 shares during the period. Bank Pictet & Cie Europe AG lifted its holdings in Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after buying an additional 2,568 shares during the period. Finally, Breed s Hill Capital LLC lifted its holdings in Eli Lilly and Company by 212.0% in the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after buying an additional 969 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 0.6%

LLY stock opened at $742.22 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $943.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $702.48 billion, a PE ratio of 48.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.47. The business has a 50 day moving average of $744.83 and a 200 day moving average of $782.72.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the company earned $3.92 EPS. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Cantor Fitzgerald dropped their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their target price for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, Guggenheim decreased their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $950.17.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.